BIXT News and Press, Bioxytran Inc

Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus BOSTON, Massachusetts, Feb 23, 2026 - (ACN Newswire) - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthroug...

Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement BOSTON, Massachusetts, Feb 17, 2026 - (ACN Newswire) - Bioxytran, Inc. (OTCMKTS: BIXT) ("Bioxytran" or the "Company"), a biotechnology company developing galectin-targe...

BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral ...

NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases , announced the e...

Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline NEENAH, WISCONSIN, Jan 29, 2026 - (ACN Newswire) - Bioxytran, Inc. (OTCQB: BIXT) ("Bioxytran" or the "Company"), a clinical-stage biotechnology company developing platform technologies spa...

BOSTON, MASSACHUSETTS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical-stage biotech company focused on innovative treatments for stroke, Alzheimer’s, and viral infections is pleased to announce the initiation of coverage of its sto...

Data from the dose optimization trial expected soon ProLectin-M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology compa...

Celestica Inc. (CLS) is expected to report $1.33 for Q3 2025 Universal Health Services Inc. (UHS) is expected to report $4.66 for Q3 2025 Dorman Products Inc. (DORM) is expected to report $2.31 for Q3 2025 Avis Budget Group Inc. (CAR) is expected to report $8.11 for Q3 2025 Two Ha...

Game changer for stroke, Alzheimer’s, and beyond Shifting from peripheral to tissue-specific oxygenation monitoring BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnolog...

Bioxytran Inc (BIXT) is expected to report for Q2 2025